OasisLMS

How do you identify patients with oligometastatic or oligoprogressive NSCLC, and what role should local therapy play in their treatment?

Explore the evolving management of oligometastatic and oligoprogressive NSCLC, including how local and systemic therapies can be integrated to inform multidisciplinary care.

Begin with Module 1 of this new 7-module microlearning series, and stay tuned for additional modules coming soon.

• Differentiate between oligometastatic and oligoprogressive NSCLC, and explain how these disease states influence multidisciplinary treatment planning.
• Describe the primary local therapy options for oligometastatic NSCLC, and identify factors that guide individualized treatment selection.
• Explain the factors that influence the timing and sequencing of local and systemic therapies in patients with oligometastatic and oligoprogressive NSCLC.
• Recognize key considerations for monitoring treatment-related toxicities, and evaluate the effectiveness of local therapy when integrated with systemic treatment.
• Discuss how regional differences in healthcare resources, access to therapies, and clinical practice influence the management of oligometastatic NSCLC. 

This activity is designed for multidisciplinary teams of medical oncologists, surgical oncologists, pathologists, histologists, clinical radiation oncologists, pulmonologists, radiologists and interventional radiologists, translational scientists, nurses, nurse practitioners, scientists, specialty pharmacists and physician associates globally.

We would like to thank the following faculty for their contributions in helping create this educational activity: 

• Nagla Karim, MD, Professor of Medicine, Director of Thoracic Oncology and Phase 1 Programs, George Washington University, Washington D.C., USA
• Delphine Antoni, MD, PhD, Radiation Oncologist, Head of Radiation Oncology Department, Istitut Strauss, Strasbourg University, Strasbourg, France
• Patrick Dorn, MD, Professor of Thoracic Surgery, Chief Surgeon and Head of the Department of Thoracic Surgery, University Hospital of Bern, Inselspital, Bern, Switzerland
• Chongrui Xu, MD, Department of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For questions, please email: education@iaslc.org.